DRUG ALLERGIES DUE TO IgE SENSITIZATION TO α-GAL

Popescu, Florin‐Dan

doi:10.31925/farmacia.2019.1.6

Cited by 3 publications

(3 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum specific IgE antibodies for non-primate mammalian carbohydrate galactose- α -1,3-galactose ( α -Gal) are associated to α -Gal syndrome with delayed allergy to red meat manifested usually as anaphylaxis after ingestion of beef, pig or lamb meat. IgE-mediated drug allergy in this syndrome was reported for some therapeutic monoclonal antibodies, such as cetuximab, snake antivenom, and varicella-zoster vaccine, but there are also risks for colloid plasma volume substitutes [ 118 ].…”

Section: Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

State-of-the-Art on Biomarkers for Anaphylaxis in Obstetrics

Simionescu

Stănescu

Popescu

2021

Life

Self Cite

View full text Add to dashboard Cite

Anaphylaxis is an unpredictable systemic hypersensitivity reaction and constitutes a high risk of maternal and fetal morbidity and mortality when occurring during pregnancy. Currently, the acute management of anaphylaxis is based on clinical parameters. A total serum tryptase is only used to support an accurate diagnosis. There is a need to detect other biomarkers to further assess high-risk patients in obstetrics. Our objective is to present biomarkers in this complex interdisciplinary approach beyond obstetrician and anaesthetic management. Candidate biomarkers derive either from mediators involved in immunopathogenesis or upcoming molecules from systems biology and proteomics. Serum tryptase is determined by singleplex immunoassay method and is important in the evaluation of anaphylactic mast cell degranulation but also in the assessment of other risk factors for anaphylaxis such as systemic mastocytosis. Another category of biomarkers investigates the IgE-mediated sensitization to triggers potentially involved in the etiology of anaphylaxis in pregnant women, using singleplex or multiplex immunoassays. These in vitro tests with natural extracts from foods, venoms, latex or drugs, as well as with molecular allergen components, are useful because in vivo allergy tests cannot be performed on pregnant women in such a major medical emergency due to their additional potential risk of anaphylaxis.

show abstract

Section: Biomarkersmentioning

confidence: 99%

“…The bovine thyroglobulin (Bos d) α -Gal carrying molecule is the molecular biomarker used in the singleplex fluorescence enzyme immunoassay with capsulated cellulose polymer as solid-phase for assessing IgE sensitization to α -Gal [ 118 ].…”

Section: Biomarkersmentioning

confidence: 99%

State-of-the-Art on Biomarkers for Anaphylaxis in Obstetrics

Simionescu

Stănescu

Popescu

2021

Life

Self Cite

View full text Add to dashboard Cite

show abstract

“…Most patients present cutaneous manifestations such as pruritus, urticaria, flushing or angioedema [40]. Other clinical manifestations such as dyspnoea, bronchospasm, diarrhoea, nausea, fever, chills and cardiovascular manifestations that may include arrhythmias and blood pressure variations have also been described [51,63]. Respiratory symptoms are second to cutaneous manifestations in frequency, while cardiovascular symptoms are less common, but more severe [9].…”

Section: Symptoms and Managementmentioning

confidence: 99%

Platinum Hypersensitivity Reactions, a Focus on Desensitisation

Havași¹

2021

FARMACIA

View full text Add to dashboard Cite

Platinum-based chemotherapy is the standard of care in a wide array of cancers. All chemotherapy, including platinum derivates, can cause hypersensitivity reactions which greatly limit their use due to the risk of anaphylaxis, forcing oncologists to use alternative chemotherapy, sometimes with a lower efficacy. The exact pathogenesis of platinum hypersensitivity reactions remains unknown, a type I mechanism is most frequently involved; however, type II, III, IV, or mixed mechanisms have also been described. Patients with atopy, a long platinum-free interval, treatment in palliative setting and higher cumulative dose are at risk of hypersensitivity. For these patients, desensitization protocols are available to treat allergic reactions to various agents, including platinum chemotherapy. Desensitization promotes antigen tolerance and allows the safe and efficient administration of the agent responsible for the hypersensitivity reaction. This review aims at providing insight into the current knowledge of platinum hypersensitivity with focus on available desensitization protocols. RezumatChimioterapia pe bază de platină este piatra de temelie în tratamentul unei game variate de cancer. Toate chimioterapicele, inclusiv derivații de platină, pot provoca reacții de hipersensibilitate care limitează mult utilizarea lor datorită riscului de șoc anafilactic, obligându-i pe oncologi să utilizeze protocoale alternative de tratament, uneori cu o eficacitate mai redusă. Patogeneza exactă a reacțiilor de hipersensibilitate la platină rămâne necunoscută, cel mai frecvent este implicat un mecanism de tip I; cu toate acestea, au fost descrise și mecanisme de tip II, III, IV sau mixte. Pacienții cu atopie, interval liber de platina prelungit, tratament cu intenție paliativă și doză cumulată de platină mai mare prezintă un risc crescut de hipersensibilitate. Pentru acești pacienți, sunt disponibile protocoale de desensibilizare care permit combaterea reacțiilor alergice la diferiți agenți, inclusiv chimioterapicele pe bază de platină. Desensibilizarea promovează toleranța la antigen și permite administrarea sigură și eficientă a agentului responsabil de reacția de hipersensibilitate. Acest review își propune să ofere o trecere în revistă a datelor actuale cu privire la hipersensibilitatea la platină, cu accent pe protocoalele de desensibilizare disponibile.

show abstract